Here at DentalBlogs, we’ve covered ViziLite and VELscope in the past. Dr. Larry Emmott takes the topic a bit further in his Dental Products Report column, “Emmott on Technology” (April 2009). Dr. Emmott reminds us that the new and improved oral cancer screening technology can’t actually diagnose oral cancer – only a biopsy can. However, these tools do, indeed, improve detection. He also says that the traditional exam simply isn’t enough. “It is the routine patient with no obvious risk factors who is most likely to be missed,” says Dr. Emmott. In addition, your patients may not know that in the head and neck exam, you check soft tissues for oral cancer. Using a ViziLite or VELscope provides an ideal situation to educate the patient about oral cancer.
But is early oral cancer detection beneficial to your practice? Dr. Emmott says yes.
Less that 2% of dentists use ViziLite or VELscope, which means, if you implement this new techology into your practice, it will set you apart.
To the patient, you appear more technologically advanced, more concerned about total oral health and wellness, and more informed.
Dr. Emmott outlines profitability in his DPR article, and you will be astonished once you see the numbers. In addition to potentially saving lives, which no monetary reward could compare to, there are true profits associated with ViziLite and VELscope exams. If you examine 1200 patients per year with either technology, profits exceed $50K .
Visit Dr. Emmott’s website here.
Read the DPR article, “Screenings Make Dollars + Sense” here.
2 responses so far ↓
1 Rebecca // Apr 18, 2009 at 4:16 pm
Bottom line: If you’re concerned with making profits that exceed 50K a year, you’re more concerned with making money than about the patient’s oral health.
2 Rebecca // Apr 18, 2009 at 4:16 pm
Bottom line: If you’re concerned with making profits that exceed 50K a year, you’re more concerned with making money than about the patient’s oral health.
Leave a Comment